Day One Biopharmaceuticals Inc DAWN.OQ DAWN.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Brisbane California California-based company is expected to report a 90.3% increase in revenue to $38.2 million from $20.07 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Day One Biopharmaceuticals Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 71.8% above its last closing price of $7.04
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.35 | -0.36 | -0.29 | Beat | 18.7 |
Mar. 31 2025 | -0.44 | -0.44 | -0.35 | Beat | 20.9 |
Dec. 31 2024 | -0.36 | -0.36 | -0.64 | Missed | -76.8 |
Sep. 30 2024 | -0.42 | -0.41 | -0.37 | Beat | 9.8 |
Jun. 30 2024 | -0.77 | -0.75 | -0.05 | Beat | 93.3 |
Mar. 31 2024 | -0.66 | -0.66 | -0.72 | Missed | -8.5 |
Dec. 31 2023 | -0.59 | -0.58 | -0.64 | Missed | -9.7 |
Sep. 30 2023 | -0.59 | -0.60 | -0.54 | Beat | 10.3 |
This summary was machine generated October 31 at 23:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)